| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 9.985 | 0 | 0 | 44.138 | 97.757 |
| Total Income - EUR | - | - | - | - | - | 9.985 | 0 | 0 | 44.276 | 98.050 |
| Total Expenses - EUR | - | - | - | - | - | 4.839 | 3.605 | 6.491 | 38.697 | 92.813 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 5.147 | -3.605 | -6.491 | 5.578 | 5.237 |
| Net Profit/Loss - EUR | - | - | - | - | - | 5.047 | -3.605 | -6.491 | 3.472 | 3.354 |
| Employees | - | - | - | - | - | 1 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - Epitomelab S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 53 | 33 | 14 | 0 | 0 |
| Current Assets | - | - | - | - | - | 8.749 | 1.221 | 17 | 15.429 | 8.823 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | 0 | 0 | 0 | 8.045 | 8.685 |
| Cash | - | - | - | - | - | 8.749 | 1.221 | 17 | 7.384 | 138 |
| Shareholders Funds | - | - | - | - | - | 5.088 | 1.371 | -5.116 | -1.628 | 1.735 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 3.777 | 0 | 15.715 | 22.666 | 8.954 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6202 - 6202" | |||||||||
| CAEN Financial Year |
6202
|
|||||||||
Comments - Epitomelab S.r.l.